Pacira BioSciences (NASDAQ: PCRX) SVP Finance sells shares under 10b5-1 plan

Rhea-AI Filing Summary

Pacira BioSciences, Inc. Senior Vice President of Finance Lauren Riker sold 6,115 shares of common stock in an open-market transaction at $23.50 per share. After the sale, she directly held 62,284.242 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026.

Insider Trade Summary 10b5-1

Net Seller: 6,115 shares ($143,703)

Net Sell 1 txn

Insider RIKER LAUREN

Role Senior Vice President, Finance

Sold 6,115 shs ($144K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,115	$23.50	$144K

Holdings After Transaction: Common Stock — 62,284.242 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 6,115 shares Sale price per share: $23.50 per share Shares held after transaction: 62,284.242 shares +1 more

4 metrics

Shares sold 6,115 shares Open-market sale of common stock on June 11, 2026

Sale price per share $23.50 per share Average price for the 6,115 shares sold

Shares held after transaction 62,284.242 shares Direct ownership following the reported sale

Trading plan adoption date March 12, 2026 Date Lauren Riker adopted Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, open-market sale, Securities Exchange Act of 1934

3 terms

Rule 10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Securities Exchange Act of 1934 regulatory

"in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RIKER LAUREN

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Finance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		S		6,115(1)	D	$23.5	62,284.242	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Pacira BioSciences (PCRX) report for Lauren Riker?

Pacira BioSciences reported that Senior Vice President of Finance Lauren Riker sold 6,115 shares of common stock. The sale was an open-market transaction at $23.50 per share, and was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026.

At what price were the Pacira BioSciences (PCRX) shares sold in this Form 4?

The reported sale of Pacira BioSciences common stock was executed at an average price of $23.50 per share. This price applies to the 6,115 shares sold in an open-market transaction disclosed in the Form 4 filed for Senior Vice President of Finance Lauren Riker.

How many Pacira BioSciences (PCRX) shares does Lauren Riker hold after the sale?

Following the reported open-market sale, Lauren Riker directly holds 62,284.242 shares of Pacira BioSciences common stock. This post-transaction holding figure is disclosed in the Form 4 and reflects her remaining direct ownership after selling 6,115 shares at $23.50 per share.

Was the Pacira BioSciences (PCRX) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states that the sale was effected under a Rule 10b5-1 trading plan. The plan was previously adopted by Lauren Riker in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on March 12, 2026.

What role does Lauren Riker hold at Pacira BioSciences (PCRX) in this Form 4 filing?

In this Form 4, Lauren Riker is identified as an officer of Pacira BioSciences, serving as Senior Vice President, Finance. The filing reports her open-market sale of 6,115 shares of common stock and provides details about pricing, remaining holdings, and the Rule 10b5-1 trading plan.